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INTRODUCTION
Rosacea is a common chronic skin and ocular condition,[1‑3] 
characterized by intermittent periods of exacerbation and 
remission.[4] Rosacea affects mainly adults around the 
age of 30  years and predominantly affects females.[5] 
Reported prevalence rates of rosacea range from 0.09% to 
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Abstract
Purpose: To describe a case of severe rosacea with ocular involvement.
Case Report: A 28‑year‑old female patient presented with extensive facial and ocular eruptions. She had 
a history of treatment with oral prednisolone due to the clinical diagnosis of lupus erythematosus (LE), 
which had resulted in transient improvement of the lesions, but was followed by exacerbation of the lesions. 
With the clinical diagnosis of severe oculofacial rosacea, she was successfully treated with oral doxycycline, 
steroid eye drops, and ocular lubricants. Histopathological features of skin biopsy were consistent with 
rosacea in the context of infection with Demodexfolliculorum. After four years, a relapse of the oculofacial 
lesions occurred, for which retreatment with oral tetracycline, steroid eye drops, and ocular lubricants was 
administered.
Conclusion:  Rosacea can be extremely severe and disfiguring, and it can be misdiagnosed as the 
pathognomonic butterfly rash of LE. Demodex carriage in rosacea is consistent and may play a significant 
role in the severe forms.
Keywords: Demodex Folliculorum; Lupus Erythematosus; Rosacea
Correspondence to:  
Abbas Bagheri, MD. Ocular Tissue Engineering Research 
Center, Shahid Beheshti University of Medical Sciences, 
No. 23, Paidarfard St., Boostan 9th St., Pasdaran Ave., 
Tehran 16666, Iran.  
E‑mail: abbasbagheri@yahoo.com
Received: 09‑03‑2016 Accepted: 03‑09‑2016
10%.[6] The pathogenesis of rosacea is poorly understood 
and controversial.[7] Characteristic facial or ocular 
inflammation in rosacea involves both the vascular 
and stromal tissue of skin. A wide spectrum of clinical 
findings of rosacea is often observed.[8] Herein, we 
describe a very severe case of rosacea with exuberant 
facial and ocular lesions.
CASE REPORT
A 28‑year‑old female patient presented to our eye 
clinic with extensive exanthematous lesions consisting 
of erythematous papules, nodules, pustules, and 
nodulocystic eruptions involving the face, forehead, 
nose, and both eyes. She had previously received oral 
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prednisolonefor lupus erythematosus  (LE), which 
resulted in transient improvement of the lesions, 
followed by severe exacerbation [Figure 1].
With the clinical diagnosis of severe oculofacial rosacea, 
the patient was treated with oral doxycycline (100 mg BID 
for two weeks), prednisolone (1% eye drops QID), and 
Artelac eye drops (Bausch & Lomb, UK limited; QID), 
leading to the improvement of the lesions [Figure 2].
All baseline laboratory investigations including the 
purified protein derivative (PPD) skin test and serum 
anti‑nuclear antibody  (ANA) were unremarkable. 
However, the erythrocyte sedimentation rate  (ESR) 
was elevated (40 mm/hour). Histological examination 
of punch biopsies of facial skin lesions revealed 
conspicuous, superficial acute inflammation intermixed 
with parakeratosis, marked acanthosis with spongiosis, 
enlarged dilated vascular channels, foci of intradermal 
chronic inflammation, and presence of Demodex 
mites within the pilosebaceous units  [Figure  3]. The 
histopathological features were consistent with rosacea. 
No histologic indicating LE was present.
After four years, she presented to our eye clinic 
with a new exacerbation of severe exudative papules 
and erythematous nodules, pustules, and nodulocystic 
lesions involving the face, forehead, nose, and left 
eye  [Figures  4 and 5]. Ocular involvement consisted 
of perilimbal injection and distinctive inferior corneal 
phlyctenules. Additionally, there were mild cutaneous 
extrafacial lesions in the anterior part of the neck, chest, 
and both forearms [Figures 6a and 6b]. During the course 
of the exacerbation, the lesions had become densely 
confluent and intensely inflammatory and exudative, 
with a crusty surface [Figure 7].
Microbiologic investigation results were negative in 
terms of the presence of fungal and bacterial elements. 
Findings of repeat histological examination of the 
skin lesions was the same as in the previous study 
and suggestive of rosacea due to Demodexfolliculorum 
infection.
Therefore, the patient was treated with oral tetracycline 
capsule  (250  mg QID for two weeks), prednisolone 
(1% eye drops QID for two weeks), and Artelac eye 
drops (TID) for several months. Gradual resolution of 
the lesions occurred. Two months later, facial erythema 
persisted, but complete resolution of the lesions was 
achieved on the eyes, neck, and both forearms [Figure 8]. 
During the last follow‑up (six months later), complete 
resolution of the facial lesions was observed [Figure 8]. 
Written consent was obtained from the patient in order 
to present her oculofacial features via photographs in 
the current case report.
DISCUSSION
Rosacea is a chronic inflammatory skin condition 
that commonly presents with facial or ocular 
involvement.[9] According to the National Rosacea 
Society  (NRS), recognition of rosacea is based mainly 
on clinical criteria divided into primary and secondary 
categories.[10] Primary criteria include transient facial 
erythema  (flushing), nontransient erythema, papules, 
pustules, and telangiectasia. The presence of one or 
more of these signs with a central facial distribution is 
considered highly indicative of rosacea, as in our case. 
Secondary diagnostic criteria are often met with one or 
more of the primary features of rosacea. They include 
burning or stinging skin sensations, elevated red plaques 
without epidermal changes, dry skin appearance, 
edema, peripheral location, ocular manifestations, and 
phymatous changes. In the present case, the ocular 
involvement was very prominent.
T h e r e  a r e  f o u r  m a i n  r o s a c e a  s u b t y p e s : 
erythematotelangiectatic, papulopustular, phymatous, 
and ocular rosacea. Variants of rosacea, which do not 
strictly match the morphologic patterns or combinations 
seen in these rosacea subtypes, may occur.[10] Our 
patient had all morphologic patterns of rosacea except 
phymatous changes.
Patients with rosacea often present with a various 
symptoms and signs of the disease, so an individualized 
treatment plan should be tailored to a patient’s unique 
clinical presentation and the exact pathophysiology of 
rosacea is poorly understood. However, most researchers 
now agree that the pathophysiology involves two primary 
factors: inflammation and vascular abnormalities. It has 
recently been proposed that innate immune mechanisms 
and changes in the regulation of the neurovascular 
system together initiate and perpetuate rosacea.[11] 
Vascular abnormalities result in blood vessel dilation 
with increased capillary permeability and edema, which 
in turn provide a favorable setting for the proliferation 
and colonization of Demodex mites. In the present case, 
the histopathological reports revealed the presence of 
Demodex in the hair follicles. Demodex mites are almost 
Figure  1. Severe papular and pustular eruptions on the 
forehead, face, and nose.
Severe Rosacea; Shirzadeh et al
Journal of ophthalmic and Vision research Volume 12, Issue 4, october-December 2017 431
always present in histological samples from individuals 
with papulopustular rosacea. This parasite stimulates 
inflammation, increasing the likelihood of papulopustular 
or granulomatous lesions. Additional inflammatory 
actions, including the release of oxygen free radicals, 
also contribute to dermal and blood vessel damage. Both 
inflammatory infiltrate and vascular changes can be easily 
observed using routine histologic staining.[12]
Rosacea manifests in a variety of clinical presentations; 
therefore, various medical therapies are available to 
treat the various signs and symptoms. Currently, there 
is no cure for the condition;[13] however, a wide range 
of medications are used for the treatment of rosacea. 
Topical medications include metronidazole, azelaic acid, 
benzoyl peroxide, antibiotics, sulfacetamide/sulfur, and 
retinoids, while oral medications used for this purpose 
include tetracyclines, metronidazole, isotretinoin, and 
macrolides.[14]
Previously available medications for rosacea have 
all targeted the inflammatory erythematous papules 
and pustules frequently associated with the disease, 
leaving a therapeutic gap for the common manifestation 
of persistent facial erythema. This “facial erythema 
treatment gap” was easily seen in the present patient 
after treatment with oral tetracycline. Brimonidine 
Figure 2. Improvement of severe papules and pustules on the 
forehead, face, nose, and in some areas of both eyes, following 
treatment with oral doxycycline.
Figure  4. Recurrence of severe papules and erythematous 
nodules, pustules, and nodulocystic lesions involving the 
forehead, face, nose, and chin.
Figure 5. Severe left eye conjunctivitis and inferior peripheral 
corneal phlyctenules.
Figure 3. Histopathological features of skin specimens. Note 
the presence of intradermal chronic inflammation (a, H and 
E, magnification ×100) together with fragments of Demodex 
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tartrate (0.33% gel) was approved by the United States 
Food and Drug Administration for the topical treatment 
of persistent facial erythema associated with rosacea. 
With its potent vasoconstrictive effects, brimonidine 
gel can lead to significant reduction of persistent facial 
erythema in the majority of patients when applied once 
a day.[9]
The differential diagnosis of rosacea largely depends 
on the pattern of rosacea. It includes systemic and discoid 
LE, acne vulgaris, seborrheic dermatitis, sarcoidosis, 
drug reactions, viral exanthema, and other systemic 
flushing disorders.[15]
The clinical similarity to LE might lead to misdiagnosis, 
particularly in patients with elevated ANA titers.[16] 
Elevated ANA titers are not infrequently found in patients 
with rosacea. Thus, less credence should be given to an 
elevated ANA titer when trying to distinguish LE from 
rosacea.[16] LE can be ruled out by clinical manifestations 
and laboratory tests. The patient in the present case 
was seronegative, and the histologic findings were not 
characteristic of LE.
In conclusion, rosacea can be an extremely severe and 
disfiguring condition, and it can be misdiagnosed as the 
pathognomonic butterfly rash of LE. Demodex carriage 
in rosacea is consistent and may play a significant role 
in its the severe forms.
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